REGV131-LNP1265

N/A

Report date: 2026/02/09 20:01:27

Base Information

Drug NameREGV131-LNP1265
Drug Alias NameREGV131-LNP1265
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9
Mechanisms of ActionGene transferenceCoagulation factor IX modulators
TargetsCoagulation factor IX
Therapy Area/IndicationsHemophilia B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesItaly +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRegeneron Pharmaceuticals IncIntellia Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesIntellia Therapeutics IncRegeneron Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsHemophilia B
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A